The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation

Maria Maślińska; Małgorzata Mańczak; Bożena Wojciechowska; Brygida Kwiatkowska

doi:10.5114/reum.2017.68909

The prevalence of ANA antibodies, anticentromere antibodies, and anti-cyclic citrullinated peptide antibodies in patients with primary Sjögren's syndrome compared to patients with dryness symptoms without primary Sjögren's syndrome confirmation

Reumatologia. 2017;55(3):113-119. doi: 10.5114/reum.2017.68909. Epub 2017 Jul 18.

Authors

Maria Maślińska¹, Małgorzata Mańczak², Bożena Wojciechowska³, Brygida Kwiatkowska¹

Affiliations

¹ Early Arthritis Clinic, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
² Department of Gerontology and Public Health, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.
³ Central Clinical Laboratory, National Institute of Geriatrics, Rehabilitation and Rheumatology, Warsaw, Poland.

Abstract

Objectives: Our study analyses the prevalence of ANA, anti-SS-A, anti-SS-B, and ACA and ACPA antibodies in patients with pSS and with dryness symptoms without pSS confirmation, and the association of ACPA and ACA antibodies with specific clinical symptoms.

Materials and methods: 113 patients were divided into two groups: I - with diagnosed pSS (N = 75); and II - with dryness without pSS evidence (N = 38). Diagnostics: indirect immunofluorescence (IF; Hep-2 cell line) of antinuclear antibodies (ANA), anti-SS-A anti-SS-B antibodies determined with semi-quantitative method, autoantibody profile (14 antigens, ANA Profil 3 EUROLINE); basic laboratory, ophthalmic examination tests, minor salivary gland biopsy with focus score (FS), joint and lung evaluation, and ESSDAI questionnaire (pSS activity).

Results: 88% of group I had ANA antibodies (1 : 320 titre), 5.3% at 1 : 160. Anti-SS-A antibodies were present in 88% of group I, including all ANA 1 : 160. Anti-SS-A antibodies positively correlated with greater and moderate activity of ESSDAI 5 (p = 0.046) and FS. The presence of SS-B antibodies significantly affected disease activity. ACPA present: group I - 13% (associated with higher arthritis incidence; p = 0.003); group II - 8%. ACA antibodies present in 4% of group I, but not in group II. No ACA association with interstitial lung changes (small ACA + group excludes full conclusions).

Conclusions: ANA antibodies should also be considered in a titre of less than 1 : 320, but the presence of anti-SS-A antibodies is still the most important immunological marker for pSS. Anti-SS-A antibodies correlate with higher disease activity (ESSDAI ≥ 5) and higher FS. The presence of the anti-SS-B antibody was significantly affected by higher activity of the disease. The incidence of arthritis was higher in patients with ACPA+ pSS compared to ACPA- (p = 0.003). There was no relationship between ACPA and arthritis in patients with dry-type syndrome without diagnosis of pSS.

Keywords: Sjögren’s syndrome; anticentromere antibodies; anticyclic citrullinated antibodies.